DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.

General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...

Strategic insight into the Liver Cancer Treatment Market reveals a high-growth opportunity, especially in Asia-Pacific, driven by a rising patient po ...

Industry Giants Gilead Sciences, Bristol Myers Squibb, AbbVie, and Merck & Co. Lead the CompetitionDublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "Liver Disease Treatments Market" report has been added ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

pylori) and hepatocellular carcinoma (HCC). These tests represent an addressable market size of more than $15 billion. Currently, celiac, respiratory multiplex and H. pylori tests have CE marks ...

Senti Biosciences, Inc.’s SNTI share price has dipped by 6.26%, which has investors questioning if this is right time to buy.

Tyra Biosciences, Inc.’s TYRA share price has dipped by 5.48%, which has investors questioning if this is right time to buy.

The "Sorafenib Market Report 2025" has been added to ResearchAndMarkets.com's offering.This Sorafenib market report provides a comprehensive analysis of the market's characteristics, size, and growth, ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy technology, today announced ...